Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Consorci Sanitari de Terrassa

Status: Enrolling

Conditions: Influenza Vaccination; COVID19; Amantadine; Antihistamine Allergy; ARB; ACE Inhibitors

Treatments: Drug: Antihistamine; Other: Influenza vaccine and COVID; Drug: ARB; Drug: Amantadine; Drug: ACEI

Study type: Observational

Funder types: Other

Identifiers

NCT04367883

02-20-161-021

02-22-161-060

Details and patient eligibility

About

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.

Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.

The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

Full description

The number COVID cases would be related to hospital admissions. Among hospital admissions, the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors) would be studied.

If patients that previously received the influenza vaccine or treated with ACEI, ARB, antihistamines or amantadine showed a better evolution, it would be proposed to extend vaccination and the inclusion of ACE inhibitors, ARB, antihistamines or amantadine in the treatment of infection.

Enrollment: 3,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.

Exclusion criteria

• None.
• For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.

Trial design

3,000 participants in 3 patient groups

Hospital admissions, postcovid syndrome and thrombosis among COVID cases in CST population

Description:

Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020. No intervention is performed.

Treatment:

Drug: ACEI

Drug: Amantadine

Drug: ARB

Other: Influenza vaccine and COVID

Drug: Antihistamine

Evolution of COVID cases in patients receiving antihistamines

Description:

COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with antihistamines. No intervention is performed.

Treatment:

Drug: Antihistamine

Evolution of COVID cases in patients receiving amantadine.

Description:

COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with amantadine. No intervention is performed.

Treatment:

Drug: Amantadine